67 related articles for article (PubMed ID: 15904908)
1. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin.
Ko WS; Guo CH; Hsu GS; Chiou YL; Yeh MS; Yaun SR
Clin Biochem; 2005 Jul; 38(7):614-20. PubMed ID: 15904908
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
6. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
8. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
11. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin.
Murakami Y; Nagai A; Kawakami T; Hino K; Kitase A; Hara Y; Okuda M; Okita K; Okita M
Nutrition; 2006 Feb; 22(2):114-22. PubMed ID: 16459223
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea.
Kim JH; Han KH; Lee KS; Park YN; Ahn SH; Chon CY; Moon YM
Yonsei Med J; 2006 Dec; 47(6):793-8. PubMed ID: 17191307
[TBL] [Abstract][Full Text] [Related]
14. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
[TBL] [Abstract][Full Text] [Related]
15. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Berg T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
[TBL] [Abstract][Full Text] [Related]
19. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Berg C; Goncales FL; Bernstein DE; Sette H; Rasenack J; Diago M; Jensen DM; Graham P; Cooksley G
J Viral Hepat; 2006 Jul; 13(7):435-40. PubMed ID: 16792536
[TBL] [Abstract][Full Text] [Related]
20. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
